You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《即日市評》恆指反覆升 成交降至不足千億 芯片股揚
受科網股跌幅收窄及藥明生物(02269.HK)升勢帶動下,恆指今日反覆造好。美聯儲局副主席克拉裏指美經濟或明年底符合加息條件,美股三大指數續創收市新高,道指及納指昨各0.3%及0.1%;執筆之時美國十年期國債孳息率升至1.486釐,美匯指數跌至94.02,美股道指期貨最新無起跌,納指期貨最新微升0.25點。人行今開展1,000億人幣7天期逆回購操作,單日淨投放900億人幣,上證綜指全日升8點或0.24%收3,507點、深證成指漲0.4%,內地創業板指數升0.9%,滬深兩市成交額共1.01萬億人民幣。 恆指高開189點後升幅收窄,中午前低見24,678點倒跌85點,午後再度上升,全日升49點或0.2%,收24,813點;國指升12點或0.14%,收8,806點;恆生科技指數升27點或0.45%,收6,221點。大市全日成交總額縮減至985.74億元,爲半年新低,滬、深港通南下交易分別淨流入3.63億及3.92億元人民幣。部份內房股受壓,碧桂園(02007.HK)股價下滑近5%,世茂集團(00813.HK)跌7%。 【藥明生物彈 獲券商看好】 藥明生物全日股價抽升10.2%收102.6元,爲升幅最大藍籌股,信達生物(01801.HK)股價彈高8.1%。中金髮表報告認爲,中資醫藥板塊經歷大幅調整,已具備配置價值,主要由於政策預期已經較爲充分,市場情緒較爲悲觀;經過大幅的調整,很多公司的估值已經進入合理區間,尤其是港股經過深度調整,性價比已逐步顯現;醫保政策本質上還是在淘汰醫藥的落後產能,使市場資源能夠更多向有創新能力的優質企業集中,醫保支出本身增速並未出現大幅下滑,新的增量領域在不斷涌現。 中金錶示,看好港股包括藥明生物、信達生物、康諾亞(02162.HK)、康方生物(09926.HK)、榮昌生物、海吉亞醫療(06078.HK)及時代天使(06699.HK)。注意風險包括藥品研發失敗,以及政策對價格壓制超預期。 【沽空率稍降 芯片股受捧】 港股今日主板市寬變動不大,主板股票的升跌比率爲22比18(上日爲22比20);恆指成份股今日21只股份上升,下跌股份30只,升跌比率爲35比50(上日爲60比37);大市今日錄沽空141.19億元,佔可沽空股份成交781.3億元的18.071%(上日18.698%)。 中芯國際(00981.HK)全日股價上揚3.9%,華虹半導體(01347.HK)漲4%。中金髮表報告,全球半導體行業去年下半年開始由於芯片缺貨,各廠商加大資本開支,行業重新進入上行週期,該行引述數據預計,今明兩年全球半導體設備市場規模分別有望達到953億及1,013億美元,其中前道設備市場規模分別爲817億及869美元。 該行指在晶圓代工或存儲器國產化趨勢下,認爲中芯國際、華虹集團、長江存儲、合肥長鑫等國內晶圓廠商有望在未來幾年維持高資本開支,驅動國內半導體設備市場規模保持增長。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account